Type of vaccine
Describes the antigens targeted. Options include pre-erythrocytic (PE), blood-stage (BS), or a combination of these plus a vaccine component targeting sexual, sporogonic, and/or mosquito (SSM) antigens to interrupt transmission from an infected person to the next.
Select one: PE, BS, PE + BS, PE + SSM, BS + SSM, PE + BS + SSM
Describes the efficacy of the vaccine immediately after completing the full regimen. For a pre-erythrocytic vaccine, efficacy against infection is defined as the proportional reduction in incidence of blood-stage infection. The user selects the level of efficacy against clinical disease, which is lower than efficacy against infection (and the model implements a mapping between the two). For a blood-stage vaccine, efficacy is defined as the proportional reduction in blood-stage parasite density. For a vaccine targeting the SSM antigens, efficacy is defined as the proportion by which the probability that a mosquito is infected during one bite is reduced .
Select one: 35%, 50%, 60%, 75%, 85%
Decay rate of efficacy against infection
Describes the time after vaccination at which the vaccine protection against infection is half of its initial value. Decay rate of efficacy assumes an exponential decay of efficacy.
Select one: 2, 4, 10 years
Future malaria transmission
Transmission is described as the percent of the population of the country of interest residing in each of five categories of entomological inoculation rate (EIR), which is a measure of how many infectious bites a person receives per year (ibpa) in a given setting. The starting transmission level for each country is derived from the reference data described below. The user can choose to keep transmission fixed at this level throughout the time period under consideration, or can enter scenarios of future transmission, for example, specific to an individual country.
See Additional file 3
Mode of vaccine delivery
Describes the means by which the vaccine is delivered to its target population. The options include routine vaccination via a country’s routine immunization system and campaign delivery.
See Table 4
Booster compliance rate
Percentage of population originally vaccinated who receive a single booster dose.